IS THAT ARTICLE FROM OCT 2009 ??Wed Oct 21, 2009 4:05pm EDT
Therinject to Bring Its Cancer Research, Intellectual Property and Former
National Cancer Institute Researcher under the Entest BioMedical Umbrella
SAN DIEGO--(Business Wire)--
Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a letter
of intent to acquire Therinject LLC. Therinject LLC is involved with Cancer
Research, marker testing / development and "bead" formation used in vaccine
development. Company Chairman David Koos noted, "Entest BioMedical has already
established a joint venture with Therinject LLC and Bio-Matrix Scientific Group
Inc. (OTCBB: BMSN). I believe this is an obvious natural fit and removes any
potential conflicts between each company`s goals."
Therinject`s Managing Principal, Steven Josephs, PhD stated, "I have been
involved with new develops taking place at Entest for some time. I`m excited
that Therinject will become an Entest company. I believe we are doing some
extremely important work in cancer treatment, COPD and potentially Multiple
Sclerosis. With the linking of these companies together, we should get further
in our research at a much faster pace."
Once a definitive agreement is in place, Therinject LLC will become a wholly
owned subsidiary of Entest BioMedical Inc. This transaction is subject to
reaching final agreement on terms and conditions.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of
Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the
development of stem cell therapy treatments for Chronic Obstructive Pulmonary
Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem
cell research applications for diabetes and other illnesses. The Company also is
involved with medical device development (including stem cell extraction
instrumentation).
Disclaimer
This news release may contain forward-looking statements. Forward-looking
statements are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying the
forward-looking statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks.
Entest BioMedical Inc.
David R. Koos, Chairman & CEO
619-702-1404 Direct
619-330-2328 Fax
info@EntestBio.com
www.EntestBio.com
Copyright Business Wire 2009
AI
